Brett R. Hagen - 26 Mar 2025 Form 4 Insider Report for Kalaris Therapeutics, Inc. (KLRS)

Role
Chief Accounting Officer
Signature
/s/ Brett R. Hagen
Issuer symbol
KLRS
Transactions as of
26 Mar 2025
Net transactions value
-$8,135
Form type
4
Filing time
27 Mar 2025, 19:19:58 UTC
Previous filing
24 Feb 2025
Next filing
11 Apr 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KLRS Common Stock Sale $8,135 -907 -32% $8.97 1,925 26 Mar 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.70 to $9.60. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2).

Remarks:

Exhibit 24.1 - Power of Attorney